Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment.
Saved in:
| Title: | Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment. |
|---|---|
| Authors: | Mijangos LRR; National Centre for Macromolecular Hydrodynamics, School of Biosciences, University of Nottingham, Sutton Bonington, UK., Harding SE; National Centre for Macromolecular Hydrodynamics, School of Biosciences, University of Nottingham, Sutton Bonington, UK., Darton NJ; Dosage Form Design and Development, AstraZeneca, BioPharmaceuticals R&D, 1 Francis Crick Avenue, Cambridge, Cambridgeshire CB2 0AA UK. |
| Source: | Biophysical reviews [Biophys Rev] 2025 Aug 02; Vol. 17 (4), pp. 1013-1031. Date of Electronic Publication: 2025 Aug 02 (Print Publication: 2025). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Springer Country of Publication: Germany NLM ID: 101498573 Publication Model: eCollection Cited Medium: Print ISSN: 1867-2450 (Print) Linking ISSN: 18672450 NLM ISO Abbreviation: Biophys Rev Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41378112 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Mijangos+LRR%22">Mijangos LRR</searchLink>; National Centre for Macromolecular Hydrodynamics, School of Biosciences, University of Nottingham, Sutton Bonington, UK.<br /><searchLink fieldCode="AU" term="%22Harding+SE%22">Harding SE</searchLink>; National Centre for Macromolecular Hydrodynamics, School of Biosciences, University of Nottingham, Sutton Bonington, UK.<br /><searchLink fieldCode="AU" term="%22Darton+NJ%22">Darton NJ</searchLink>; Dosage Form Design and Development, AstraZeneca, BioPharmaceuticals R&D, 1 Francis Crick Avenue, Cambridge, Cambridgeshire CB2 0AA UK. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101498573%22">Biophysical reviews</searchLink> [Biophys Rev] 2025 Aug 02; Vol. 17 (4), pp. 1013-1031. <i>Date of Electronic Publication: </i>2025 Aug 02 (<i>Print Publication: </i>2025). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>101498573 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1867-2450 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2218672450%22">18672450 </searchLink><i>NLM ISO Abbreviation: </i>Biophys Rev <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41378112 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12551-025-01346-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1013 Titles: – TitleFull: Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mijangos LRR – PersonEntity: Name: NameFull: Harding SE – PersonEntity: Name: NameFull: Darton NJ IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 08 Text: 2025 Aug 02 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 1867-2450 Numbering: – Type: volume Value: 17 – Type: issue Value: 4 Titles: – TitleFull: Biophysical reviews Type: main |
| ResultId | 1 |
